Business Description
BioGend Therapeutics Co Ltd
NAICS : 325412
SIC : 2834
ISIN : TW0006733009
Description
Financial Strength
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 61.12 | |||||
Equity-to-Asset | 0.93 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.13 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 42.24 | |||||
Beneish M-Score | -1.65 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 285.1 | |||||
3-Year EBITDA Growth Rate | 12.8 | |||||
3-Year EPS without NRI Growth Rate | 7.6 | |||||
3-Year FCF Growth Rate | -1.1 | |||||
3-Year Book Growth Rate | 0.4 |
Momentum Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 25.6 | |||||
9-Day RSI | 29.67 | |||||
14-Day RSI | 34.52 | |||||
6-1 Month Momentum % | 5.67 | |||||
12-1 Month Momentum % | 9.14 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 25.33 | |||||
Quick Ratio | 24.81 | |||||
Cash Ratio | 22.15 | |||||
Days Inventory | 188.13 | |||||
Days Sales Outstanding | 74.18 | |||||
Days Payable | 24.11 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -9.7 | |||||
Shareholder Yield % | 0.06 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 80.54 | |||||
Operating Margin % | -88.7 | |||||
Net Margin % | -70.18 | |||||
FCF Margin % | -72.92 | |||||
ROE % | -11.87 | |||||
ROA % | -10.9 | |||||
ROIC % | -44.38 | |||||
ROC (Joel Greenblatt) % | -122.62 | |||||
ROCE % | -13.76 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Forward PE Ratio | 115.87 | |||||
PS Ratio | 28.52 | |||||
PB Ratio | 5.1 | |||||
Price-to-Tangible-Book | 6.09 | |||||
EV-to-EBIT | -28.65 | |||||
EV-to-EBITDA | -47.88 | |||||
EV-to-Revenue | 24.65 | |||||
EV-to-FCF | -34.24 | |||||
Price-to-Net-Current-Asset-Value | 6.79 | |||||
Price-to-Net-Cash | 7.88 | |||||
Earnings Yield (Greenblatt) % | -3.49 | |||||
FCF Yield % | -2.55 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
BioGend Therapeutics Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil NT$) | 156.644 | ||
EPS (TTM) (NT$) | -0.88 | ||
Beta | 0.65 | ||
Volatility % | 24.35 | ||
14-Day RSI | 34.52 | ||
14-Day ATR (NT$) | 0.740787 | ||
20-Day SMA (NT$) | 37.1525 | ||
12-1 Month Momentum % | 9.14 | ||
52-Week Range (NT$) | 31.4 - 42.85 | ||
Shares Outstanding (Mil) | 124.26 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
BioGend Therapeutics Co Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
BioGend Therapeutics Co Ltd Stock Events
Event | Date | Price(NT$) | ||
---|---|---|---|---|
No Event Data |
BioGend Therapeutics Co Ltd Frequently Asked Questions
What is BioGend Therapeutics Co Ltd(ROCO:6733)'s stock price today?
When is next earnings date of BioGend Therapeutics Co Ltd(ROCO:6733)?
Does BioGend Therapeutics Co Ltd(ROCO:6733) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |